Could Affimed NV (NASDAQ:AFMD) Go Up After Its Newest Short Interest Report?

June 20, 2017 - By Vivian Currie

 Could Affimed NV (NASDAQ:AFMD) Go Up After Its Newest Short Interest Report?

The stock of Affimed NV (NASDAQ:AFMD) registered an increase of 7.21% in short interest. AFMD’s total short interest was 886,200 shares in June as published by FINRA. Its up 7.21% from 826,600 shares, reported previously. With 201,000 shares average volume, it will take short sellers 4 days to cover their AFMD’s short positions. The short interest to Affimed NV’s float is 3.19%.

About 88,084 shares traded. Affimed NV (NASDAQ:AFMD) has declined 19.09% since June 20, 2016 and is downtrending. It has underperformed by 35.79% the S&P500.

Affimed N.V. is a clinical-stage biopharmaceutical firm focused on discovering and developing cancer immunotherapies. The company has market cap of $93.81 million. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. It currently has negative earnings. The Company’s pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs.

Affimed NV (NASDAQ:AFMD) Ratings Coverage

Among 7 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Affimed Therapeutics has $19 highest and $4 lowest target. $10.60’s average target is 400.00% above currents $2.12 stock price. Affimed Therapeutics had 13 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer with “Outperform” on Thursday, August 6. The stock of Affimed NV (NASDAQ:AFMD) earned “Sell” rating by Zacks on Monday, August 10. As per Thursday, September 3, the company rating was upgraded by Zacks. The rating was downgraded by Leerink Swann to “Market Perform” on Thursday, May 19. The rating was initiated by Wells Fargo with “Outperform” on Friday, December 4. The stock of Affimed NV (NASDAQ:AFMD) has “Outperform” rating given on Tuesday, April 12 by BMO Capital Markets. The stock of Affimed NV (NASDAQ:AFMD) has “Market Perform” rating given on Friday, August 12 by Leerink Swann. Jefferies maintained the stock with “Hold” rating in Thursday, May 19 report. Laidlaw initiated it with “Buy” rating and $15 target in Thursday, December 10 report. The firm earned “Hold” rating on Wednesday, September 9 by Jefferies.

More important recent Affimed NV (NASDAQ:AFMD) news were published by: which released: “Affimed Reports Financial Results for First Quarter 2017” on May 17, 2017, also published article titled: “Affimed Reports Financial Results for Second Quarter 2016 and Provides …”, published: “Affimed Announces Pricing of Public Offering of Common Stock” on January 20, 2017. More interesting news about Affimed NV (NASDAQ:AFMD) was released by: and their article: “Affimed to Present Immune Cell Engager Data at ASCO Annual Meeting and EACR …” with publication date: May 17, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.